| Rios And Associates Therapeutic Solutions, Llc | |
|
638 Newark Ave Jersey City NJ 07306-2306 | |
| (203) 507-4703 | |
| Not Available |
| Full Name | Rios And Associates Therapeutic Solutions, Llc |
|---|---|
| Speciality | Preferred Provider Organization |
| Location | 638 Newark Ave, Jersey City, New Jersey |
| Authorized Official Name and Position | Juan Antonio Rios (OWNER) |
| Authorized Official Contact | 2035074703 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Rios And Associates Therapeutic Solutions, Llc 638 Newark Ave Jersey City NJ 07306-2306 Ph: (203) 507-4703 | Rios And Associates Therapeutic Solutions, Llc 638 Newark Ave Jersey City NJ 07306-2306 Ph: (203) 507-4703 |
| NPI Number | 1144561614 |
|---|---|
| Provider Enumeration Date | 03/08/2013 |
| Last Update Date | 05/09/2023 |
| Certification Date | 05/09/2023 |
| Medicare PECOS PAC ID | 3274994546 |
|---|---|
| Medicare Enrollment ID | O20230802003424 |
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
A recent study by Merikangas and colleagues published in the January 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry shows that only half of adolescents that are affected with severely impairing mental disorders ever receive treatment for their disorders.
The No. 1, free medical-texting solution is unveiling a faster platform that handles attachments during a launch party on June 19 near Fenway Park.
Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144561614 | NPI | - | NPPES |
| Provider Name | Juan Rios |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1790024008 PECOS PAC ID: 8628479425 Enrollment ID: I20210630003821 |
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
A recent study by Merikangas and colleagues published in the January 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry shows that only half of adolescents that are affected with severely impairing mental disorders ever receive treatment for their disorders.
The No. 1, free medical-texting solution is unveiling a faster platform that handles attachments during a launch party on June 19 near Fenway Park.
Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.
› Verified 1 days ago
| Provider Name | Priscilla J Carmona |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1306524921 PECOS PAC ID: 4486018561 Enrollment ID: I20230907002150 |
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
A recent study by Merikangas and colleagues published in the January 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry shows that only half of adolescents that are affected with severely impairing mental disorders ever receive treatment for their disorders.
The No. 1, free medical-texting solution is unveiling a faster platform that handles attachments during a launch party on June 19 near Fenway Park.
Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.
› Verified 1 days ago
| Provider Name | Tanasha Driver |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1982332441 PECOS PAC ID: 4385098037 Enrollment ID: I20230928002082 |
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
A recent study by Merikangas and colleagues published in the January 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry shows that only half of adolescents that are affected with severely impairing mental disorders ever receive treatment for their disorders.
The No. 1, free medical-texting solution is unveiling a faster platform that handles attachments during a launch party on June 19 near Fenway Park.
Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.
› Verified 1 days ago
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
A recent study by Merikangas and colleagues published in the January 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry shows that only half of adolescents that are affected with severely impairing mental disorders ever receive treatment for their disorders.
The No. 1, free medical-texting solution is unveiling a faster platform that handles attachments during a launch party on June 19 near Fenway Park.
Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.
› Verified 1 days ago
Stay Focused Therapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 92 Wayne St, Jersey City, NJ 07302 Phone: 201-381-0810 | |
Christ Hospital Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 179 Palisade Ave, Jersey City, NJ 07306 Phone: 201-795-8375 | |
Intense Behavioral Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 120 Seaview Ave, Jersey City, NJ 07305 Phone: 201-434-4240 Fax: 201-946-4240 | |
Beacon Health And Wellness Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 Montgomery St Ste 2, Jersey City, NJ 07302 Phone: 201-776-8610 | |
Growing Stronger Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 123 Town Square Pl # 273, Jersey City, NJ 07310 Phone: 732-419-7353 | |
Clear Path Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 Hudson St Fl 21, Jersey City, NJ 07302 Phone: 201-677-2106 Fax: 201-603-6986 | |
Gmhc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 343 8th St, Jersey City, NJ 07302 Phone: 551-574-0523 |